Search results for "chronic"

showing 10 items of 3309 documents

Relationship between aortic root size and glomerular filtration rate in hypertensive patients

2016

OBJECTIVE: Recent studies suggest that enlarged aortic root diameter (ARD) may predict cardiovascular events in absence of aneurysmatic alterations. Little is known about the influence of renal function on ARD. Our study was aimed to assess the relationships between glomerular filtration rate (GFR) and ARD in hypertensive subjects. METHODS: We enrolled 611 hypertensive individuals (mean age: 52 ± 15 years; men 63%). ARD was measured by echocardiography at the level of Valsalva's sinuses using M-mode tracings. It was considered as absolute measure, normalized to body surface area (ARD/BSA) and indexed to height (ARD/H). GFR was estimated by the Chronic Kidney Disease Epidemiology Collaborati…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyBody Surface AreaAortic DiseasesRenal functionAorta Thoracic030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicine.arterySeverity of illnessEpidemiologyInternal MedicinemedicineHumans030212 general & internal medicineRenal Insufficiency ChronicAgedBody surface areaSettore MED/14 - NefrologiaAortaaortic root diameter arterial hypertension cardiovascular risk chronic kidney disease echocardiography glomerular filtration ratebusiness.industryConfoundingOrgan SizeMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareCardiovascular DiseasesEchocardiographyHypertensionCardiologyLinear ModelsPopulation studyFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration Rate
researchProduct

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

An Integrative Cognitive Behavioral Therapy Program for Adults With Migraine: A Feasibility Study

2019

Objective To present a novel cognitive behavioral therapy program that was developed exclusively for adults with migraine, and to assess the feasibility of this program. Background Unlike previous efforts, we combined different approaches of behavioral therapy into one program: relaxation therapy, cognitive behavioral therapy, trigger management. Methods The treatment program consists of 7 sessions (including psychoeducation, lifestyle counseling, coping with fear of attacks, trigger management, and stress management). The research was conducted in a single-group study with N = 9 completers (age: M = 41.6, SD = 17.6 years; N = 8 female, N = 1 male; N = 5 migraine without aura, N = 2 migrain…

AdultMalemedicine.medical_specialtyStress managementMigraine Disordersmedicine.medical_treatmentlaw.inventionGroup psychotherapy03 medical and health sciences0302 clinical medicineChronic MigraineRandomized controlled triallawAdaptation PsychologicalPsychoeducationHumansMedicine030212 general & internal medicineIntegrative MedicineCognitive Behavioral Therapybusiness.industryMiddle Agedmedicine.diseaseMigraine with auraCognitive behavioral therapyNeurologyMigrainePhysical therapyFeasibility StudiesFemaleNeurology (clinical)medicine.symptombusinessRisk Reduction BehaviorStress Psychological030217 neurology & neurosurgeryHeadache: The Journal of Head and Face Pain
researchProduct

Impact of chronic psychosocial stress on autonomic cardiovascular regulation in otherwise healthy subjects.

2005

Elevated psychosocial stress might favor the occurrence of cardiovascular disease; however, mechanisms are incompletely understood. We hypothesized that patients (n=126; 44±1 years of age) referred to an internal medicine clinic because of symptoms related to chronic psychosocial stress would demonstrate signs of autonomic dysregulation compared with controls (n=132; 42±1 years of age). We used autoregressive spectral analysis of RR interval variability to obtain indirect markers of sympathetic and of vagal (respectively, low-frequency and high-frequency components, both expressed in normalized units) oscillatory modulation of sinoatrial node, as well as of sympathetic vasomotor regulation…

AdultMalemedicine.medical_specialtySympathetic Nervous SystemPostureCardiac indexBlood PressureBaroreflexAutonomic Nervous SystemCardiovascular SystemHeart RateInternal medicineSurveys and QuestionnairesInternal MedicineMedicineAutonomic dysregulationHumansPsychologySinoatrial NodeVasomotorbusiness.industrySinoatrial nodeVagus NerveBaroreflexVasomotor SystemAutonomic nervous systemmedicine.anatomical_structureBlood pressureEndocrinologyCase-Control StudiesChronic DiseaseFemaleautonomic nervous system stress risk factors baroflex behavior hypertension arterialMED/09 - MEDICINA INTERNAbusinessPsychosocialStress PsychologicalHypertension (Dallas, Tex. : 1979)
researchProduct

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

2006

BACKGROUND The efficacy of consensus interferon (CIFN), a synthetic IFN with optimised in vitro activity, was assessed in chronic hepatitis C virus (HCV) patients who had failed the pretreatment with interferon-alpha (IFNalpha) and ribavirin. METHODS One hundred and three patients after non-response (n=69) or relapse (n=34) to IFNalpha+/-ribavirin were randomly assigned to high-dose induction (CIFN 27-->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) or low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks); each with ribavirin 800 mg/day. Follow-up was 24 weeks. RESULTS Non-responder patients treated with high-dose induction had higher early virolo…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentConsensus interferonAlpha interferonHepacivirusGastroenterologyAntiviral AgentsVirusVirological responsechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinMedicineHumansIn patientDosingProspective StudiesAgedHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis C ChronicMiddle AgedViral Loaddigestive system diseasesTreatment OutcomechemistryResearch DesignImmunologyFemaleInterferonsbusinessBiomarkersFollow-Up StudiesLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

2011

Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.We treated 398 treatment-naïve patients who had HCV genotype 1 infections with pegylated interferon alfa-2b and ribavirin for 24, 30, 36, 42, 48, 60, or 72 weeks (mean of 39 weeks, termed individualized therapy); the duration of therapy was determined based on baseline viral load and the time point at which HCV RNA levels became undetectable (measured at weeks 4, 6, 8, 12, 24, and 30). Results were compared with…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeTranscription-mediated amplificationHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyVirusPolyethylene GlycolsYoung AdultLiver diseasechemistry.chemical_compoundPegylated interferonGermanyInternal medicineRibavirinHumansMedicinePrecision MedicineAgedDose-Response Relationship DrugHepatologybusiness.industryStandard treatmentRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical trialTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drugGastroenterology
researchProduct

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late ch…

2007

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classAntineoplastic AgentsBiologyGastroenterologyTyrosine-kinase inhibitorDisease-Free SurvivalPiperazinesMedian follow-upInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase InhibitorsSurvival analysisAgedRetrospective StudiesHematologyImatinibHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLeukemiaImatinib mesylatePyrimidinesImmunologyBenzamidesImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugAmerican journal of hematology
researchProduct

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

2006

Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alpha-2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 microg/kg peginterferon alpha-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPegylated interferon alpha-2b610 MedizinInterferon alpha-2GastroenterologyPolyethylene GlycolsInterferonInternal medicineMedicineHumansAgedHepatologybusiness.industryInterferon-alphaMiddle AgedHepatitis CRecombinant ProteinsClinical trialChronic infectionCytokineImmunologyAcute DiseasePopulation studyPatient ComplianceFemaleViral diseaseAcute hepatitis Cbusinessmedicine.drugHepatology (Baltimore, Md.)
researchProduct

Long-term course of interferon-treated chronic hepatitis C

1998

Abstract Background/Aims: To evaluate whether sustained response to α-interferon improves clinical outcome in patients with chronic hepatitis C. Methods: A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with α-interferon in two trials (mean follow-up 62.1 months, range 7–109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of α-2b or α-n1 interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon. Results: Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. …

AdultMalemedicine.medical_specialtyTime FactorsCirrhosisHepacivirusHepatitis C virusStatistics as TopicAlpha interferonmedicine.disease_causeAntiviral AgentsGastroenterologyLiver diseaseInternal medicineAscitesmedicineHumansInterferon alfaHepatologybiologybusiness.industryInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseTreatment OutcomeImmunologyFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria

2019

Objectives: Treatment of chronic spontaneous urticaria (CSU) is based on evidence-based guidelines. However, specific patient needs and benefits from therapy have not been differentiated on the guideline level. The current study was designed to use the first part of the PBI, the PNQ, to characterize[for full text, please go to the a.m. URL]

AdultMalemedicine.medical_specialtyTime FactorsCross-sectional studyHealth StatusDermatologyDiseasePatient Care Planning030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineCost of IllnessQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansChronic UrticariaDisease burdenChronic urticariaAgedbusiness.industryPruritusPatient PreferenceGuidelineMiddle Aged610 Medical sciences; MedicineCross-Sectional StudiesPatient burden030228 respiratory systemddc: 610Quality of LifeItchingFemalemedicine.symptombusinessDecision Making SharedNeeds Assessment
researchProduct